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Rationale: This Report was developed by the Feline Vaccination Advisory Panel of the
American Association of Feline Practitioners (AAFP) to provide practical recommendations 
to help clinicians select appropriate vaccination schedules for their feline patients based 
on risk assessment. The recommendations rely on published data as much as possible, 
as well as consensus of a multidisciplinary panel of experts in immunology, infectious
disease, internal medicine and clinical practice. 
Introduction
The AAFP produced the first organization-
driven vaccination guidelines in 1998. These
were updated in 2000 and again in 2006.1 Each
version has offered a comprehensive review
of the literature and has provided recom -
mendations for vaccine protocols based on
known science along with some extrapolation
between studies and between species when
feline studies were not available. This Report
has used the same criteria.
The practicing veterinarian is in the best
position to determine how to put these
Guidelines into practice for an individual
patient. The veterinarian should undertake a
clinical risk/benefit assessment for each ani-
mal and discuss recommended vaccination
schedules with the owner so that they can
make an informed choice. The assessment
should include discussion on the likelihood 
of exposure, the health and lifestyle of the 
animal, and the risks related to vaccination. 
The Advisory Panel recognizes that situa-
tions differ in different countries, and that
every country will have slightly different
issues and priorities; thus these Guidelines
will not necessarily be applicable to every
country and the practitioner must interpret
accordingly.
The three international panels that have
produced feline vaccination guidelines
(AAFP, World Small Animal Veterinary
Association and European Advisory Board on
Cat Diseases) recommend that an annual
health examination be performed irrespective
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of whether vaccines are administered.
While the optimal frequency of health
examinations for cats is
unknown, it is generally
The AAFP welcomes
endorsement of these guide-
lines by the International
Society of Feline
Medicine (ISFM).
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accepted that healthy adult cats should be
examined at least once a year. In the past,
annual veterinary visits were structured
around vaccinations as the primary focus.
With the increasing body of knowledge about
duration of immunity (DOI) from vaccina-
tions, their potential adverse effects, and the
increased awareness of pet owners about
these issues, it is clear that vaccination no
longer justifies the need for annual visits.
Practitioners are encouraged
to help cat owners understand
the value of regular health care
and that it ideally should be
proactive rather than reactive.
A useful approach is for health
care to be tailored to the vari-
ous feline life stages, which
improves early recognition of
potential health-related issues
and can facilitate treatment.2
A Pet Owner Guide, dis-
cussing the risks and benefits
of vaccination, is included as
Appendix 2 (pages 807 and
808).
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Vaccination principles
Vaccination plays an important role in the con-
trol of infectious diseases, both for an individ-
ual as well as for the cat population (ie, herd
health). Some vaccine antigens are also used to
lessen the potential for zoonotic spread of 
disease (eg, rabies). The benefits of routine and
widespread vaccination are clear: the inci-
dence of serious disease caused by highly
pathogenic organisms, such as feline parvo -
virus (panleukopenia), can be reduced in 
populations in which widespread vaccination
is practised. However, the level of protection
conferred by a particular vaccine in an individ-
ual patient varies. The quality of vaccine-
induced immunity in any patient is influenced
by a complex interaction of factors unique to
the individual patient, the patient’s environ-
ment, and the nature of the vaccine and
pathogen. Precisely predicting either the out-
come of vaccination or subsequent exposure to
a pathogen is difficult (or impossible) and,
therefore, vaccination should never be offered
as a guarantee of protection.
The risk of infection and subsequent devel-
opment of disease varies with a number of 
factors including the age and health of the cat,
magnitude of exposure to the infectious agent,
the pathogenicity of individual agents, the
geographic prevalence of infection and the
vaccination history of the cat. Some of the fac-
tors that negatively affect an individual ani-
mal’s ability to respond to vaccination include
interference from maternally derived antibod-
ies (MDA), congenital or acquired immuno-
deficiency, concurrent disease or infection,
inadequate nutrition, immunosuppressive
medications, chronic stress and an aging
immune response. Additionally, some vaccinal
agents (eg, FPV) will induce a much stronger
protective immune response than others (eg,
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What’s new in this version
< Updated recommendations on vaccination
frequency and interval
< Vaccination recommendations for specific
situations
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< Frequently asked questions
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feline injection-site sarcoma risk reduction
At least once 















Information presented in depth in the
2006 AAFP Feline Vaccine Advisory Panel




< Vaccination in kitten socialization
classes
< Appendix 1: Certificate of Exemption
from Rabies Vaccination 
< Appendix 3: Vaccination documentation
< Appendix 4: Vaccine handling and
storage
< Appendix 5: Vaccine preparation
< Appendix 6: Vaccine administration tips
This material may be found in the 
2006 Guidelines posted at:
http://www.catvets.com/guidelines/
practice-guidelines/feline-vaccination
Figure 1 Kittens are more
susceptible to infection 
than adult cats are, and are 
a principal primary target
population for vaccination.
Courtesy of Dr Deb Givin
Patient risk variables to
take into consideration
< Age of cat
< Health of cat












< Aging immune response
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feline herpesvirus [FHV-1]). As vaccine-afford-
ed protection against both infection and dis-
ease is thus variable and not absolute, exposure
to infected animals and infectious agents
should be minimized, even after vaccination.
Kittens are generally more susceptible to infec-
tions than adult cats are and typically develop
more severe disease (Figure 1). Thus, they repre-
sent a principal primary target population for
vaccination. As part of a routine health care pro-
gram, the vaccination needs of all cats, including
adults, should be assessed at least once a year, in
conjunction with a comprehensive physical
examination and consultation, modifying 
vaccination recommendations as necessary on
the basis of altered risk/benefit ratio.
Vaccination is a medical procedure, and the
decision to vaccinate, even with core vaccines
(see box above), should be based on a
risk/benefit assessment for each cat and for
each vaccine antigen. Vaccination may indeed
be beneficial, but it is not innocuous, and the
benefit of vaccinating an animal (eg, the
induction of clinically meaningful immunity)
must be balanced against the risk of adverse
events, likelihood of exposure and severity of
disease. Where practical, every effort should
be made to ensure that cats are healthy prior
to vaccination; however, concurrent illness
should not necessarily preclude vaccination.
The overall objectives of vaccination are
shown on the right.
General information on types of
feline vaccines
Vaccines, including different products
licensed to protect against the same pathogen,
are not necessarily alike. Different vaccine
technologies may directly influence efficacy,
safety, DOI and route of administration of
individual products. Awareness of funda -
mental differences is necessary.
The following terminology is used through-
out these Guidelines to describe types of 
vaccines: inactivated (killed), modified-live
(attenuated) and recombinant. The attributes of
each vaccine type are summarized in Table 1.
Characteristics of vaccine types have been
reviewed as recently as 2011.3All veterinary vac-
cines, prior to licensing, are subjected to testing
for efficacy, safety, potency and purity.  Testing
methods may vary among different manufac-
turers and licensing authorities. While all
licensed vaccines need to meet minimum effica-
cy standards, the level of protection induced can
vary depending on many factors, including the
method used to manufacture the product. For
further information on licensing, readers should
refer to the 2006 Guidelines (see box on page
786) and to individual licensing authorities
(United States Department of Agriculture
[USDA]; Canadian Food Inspection Agency
[CFIA]; Veterinary Medicines Directorate
[VMD], Department for Environment, Food,
and Rural Affairs [DEFRA], UK; European
Medicines Agency [EMA], EU).
The principal differences between inactivat-
ed, modified-live and recombinant vaccines
are discussed below.
< Inactivated vaccines Vaccinal pathogens
can be completely inactivated (ie, killed) by
various means, eliminating risk of replication
post-inoculation or ‘reversion to virulence’.
For these reasons, inactivated vaccines have
historically been regarded as the safest
vaccines. However, the inclusion of a variety
of extraneous chemicals (stabilizers,
preservatives), antibiotics, adjuvants and
excipient proteins has been implicated as a
cause of both acute and delayed adverse
reactions in cats.4
< Modified-live vaccines For some agents,
intact pathogens can be modified so that they
Core versus von-core
< The Advisory Panel has revised which vaccines are
considered core and non-core, recognizing that antigens
other than feline parvovirus, herpesvirus-1 and calicivirus
may not be required or available in all situations or in all
countries. The specific circumstances in which non-core
vaccines may be appropriate vary considerably. 
< CORE VACCINES are those recommended for all cats. 
The Advisory Panel recommends that feline panleukopenia
(FPV), feline herpesvirus-1 (FHV-1) and feline calicivirus
(FCV) vaccines fall into this category.  
< NON-CORE VACCINES should be administered to cats 
in specific risk categories on the basis of an individual
risk/benefit assessment. The Advisory Panel believes 
that rabies, feline leukemia virus (FeLV), feline
immunodeficiency virus (FIV), Chlamydophila felis,
Bordetella bronchiseptica, feline infectious peritonitis (FIP)
and dermatophyte vaccines fall into this category. 
< Vaccination against rabies is essential in regions where 
it is required by statute/law or where the virus is endemic. 
< The Advisory Panel recommends that all cats under 1 year 
of age be vaccinated against FeLV and receive a booster
vaccination 1 year later. After 1 year of age, the need for
subsequent vaccination is determined by risk factors that 
the individual is exposed to. 
The reader is referred to the section on risk/benefit assessment (pages 788–789) and the accompanying Disease
Information Fact Sheets (details on page 799) for further specifics regarding each vaccine antigen.
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retain the ability to replicate in the host and
provoke an immune response, but not cause
clinical disease. Altered pathogenicity
effectively induces subclinical infection and
can result in a more rapid onset of immunity
for some vaccine antigens than with
comparable inactivated vaccines.5,6 All
bacterial and viral vaccines licensed for
mucosal (intranasal) administration are
modified-live, as are a number of injectable
vaccines.
< Recombinant vaccines Discrete genetic
sequences can be isolated from a pathogenic
virus or bacterium that encode immunogenic
proteins. These sequences can either be
recombined with the DNA of a live, 
non-pathogenic virus, which can then be
administered as a vaccine (vectored vaccine),
or they may be inserted in bacterial plasmids
to enable in vitro production of antigens 
that can be harvested and purified for
incorporation into a vaccine (ie, subunit
vaccine). Examples of both types of vaccines
are licensed for use in veterinary medicine.  
Risk/benefit assessment
In assessing the risk for an individual cat,
information about the cat, the environment
and infectious agents to which the cat will be
realistically exposed needs to be considered.
Specifically, questions need to be asked that
address the cat’s lifestyle as well as the
lifestyle of any other cats in the same house-
hold. Queries should also be posed regarding
other sources of exposure, such as excursions
outside the home, boarding and travel.
Patient
Age is an important element in assessing an
individual’s risk profile. Most infectious dis-
eases are more prevalent in kittens, and kit-
tens less than 6 months old are generally more
susceptible to infection and disease than adult
cats are. Kittens, therefore, represent a princi-
pal primary target population for vaccination.
MDA provide important protection for the
kitten, but may also interfere with, or neutral-
ize, vaccines. As the level of MDA varies
among individuals, the age at which a kitten
may be able to respond to vaccination will
also vary, and in some cases may be 16 weeks
or older. While information is available on the
variability of MDA as pertains to FHV-1, FCV
and FPV, limited data is available for other
antigens; thus the role of MDA in interference
with vaccination against rabies, FeLV or other
pathogens is unknown. Stopping a vaccina-
tion course too early (when MDA are still
interfering) is thought to be the single 
most common cause of vaccination failure in
kittens. 
Inactivated (killed) Modified-live (attenuated) Recombinant
Examples Panleukopenia, herpesvirus-1,








Does not replicate (non-infectious) May replicate locally and in sites
beyond the inoculation site (infectious)
Does not replicate (non-infectious)
Initial vaccination, in the
absence of maternal antibody
NB It is not practical to 
determine the persistence of
MDA for individual kittens; 
vaccination until ≥16 weeks 
of age is advisable
Two initial doses are required, 3–4
weeks apart. Protective immunity is
expected within 7–10 days following
the second dose. 
Rabies vaccine is the exception as
only one initial dose is required; 
protective immunity is expected to
develop by 28 days
Two initial doses are required, 3–4
weeks apart. Protective immunity is
expected within 7–10 days following
the second dose
rRabies: One dose is required.
Protective immunity is expected to
develop by 28 days.
rFeLV: Two initial doses are required,
3–4 weeks apart. Protective 
immunity is expected within 7–10
days following the second dose  
Route(s) of administration 
as stipulated by the
manufacturer
Injectable: SC or IM* Injectable: SC or IM*
Mucosal: Intranasal (IN)**
Injectable: SC
Adjuvanted Yes – the majority Not required Some individual products contain 
an adjuvant
Therapeutic indications Dermatophytosis (in some 
European countries)
None None
Reversion to virulence Not possible Theoretically possible, 
but highly unlikely
Not possible
NB Availability of different vaccines (type, antigen and route of administration) varies among countries
*The Advisory Panel recommends that when a vaccine is designed for either subcutaneous (SC) or intramuscular (IM) use, the SC route is used,
both for patient comfort as well as for earlier detection of injection-site sarcomas
**Several products (two FHV-1, FCV; one FPV, FHV-1, FCV; Bordetella; FIP) are licensed for intranasal administration, though availability varies
among countries
MDA = maternally derived antibodies, r = recombinant
Table 1 Examples of different types of feline vaccines and their attributes 
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Patient’s environment
Population density and opportunity for expo-
sure to other cats (eg, whether the cat is free-
roaming or has access to the outdoors) are
among the most critical issues affecting risk of
exposure to an infectious agent. Cats and kittens
living in multiple-cat households and environ-
ments (eg, boarding, breeding, foster or shelter
facilities) are likely to have a substantially high-
er risk of infection than are cats living indoors in
one- or two-cat households. Furthermore, the
introduction of new cats into a household poses
a potential risk – not only to the cat entering the
household, but also to the whole group because
of possible exposure to new infectious agents.
The immunosuppressive effects of stress 
inherent in the change of social demographics
may also result in recrudescence and an
increased susceptibility to infection and disease.
Conversely, cats that are naturally exposed to
infectious agents after vaccination may have an
opportunity for ‘natural boosting of immunity’
that may not be afforded to cats kept alone.
Indoor cats generally have a low risk of
exposure to infectious agents, particularly
where the agent in question is only transmitted
by direct contact among cats. However, they
may also be exposed to infection from other
cats in the household (ie, subclinically infected
or carrier cats), or by indirect transmission of
pathogens brought in from outside on owners’
clothing, shoes, etc. In theory, strictly indoor
cats may be more susceptible to developing
panleukopenia because they do not receive
boosting through the possibility of natural
exposure. It is important to ask owners about
other exposure that indoor cats may have, 
such as supervised visits out of doors (eg, on
harness/leash, in the garden, etc), visiting
other cats in an apartment building, balconies
or roof gardens, visiting cats that belong to
other family members, and staying in boarding
facilities. Fostering shelter cats alters the risk
for the resident cats, both through potential
direct exposure to infectious agents as well as
through stress-induced immunosuppression.
Trap–neuter–return (TNR) and other special
situations are discussed on pages 791–794.
Geographic distribution of infectious agents
may result in substantially different risks of
exposure for cats living in different areas 
(eg, rabies). Questions regarding future travel
should be included in determining the risk 
of exposure to specific infectious agents.
Periodic housing in boarding facilities, shel-
ters or breeding facilities or other multiple-cat
households also places cats at increased risk
of exposure to a variety of infectious agents,
although the risk will vary substantially
between different situations. 
Infectious agent
Independent agent-associated variables, such
as virulence, strain variation and mutation,
challenge dose and stability in the environ-
ment, influence the outcome of infection.
These are difficult to assess objectively.
Recommendations for
vaccination of household 
pet cats 
Developing universal guidelines for vaccina-
tion of household pet cats is complicated by
the lack of a clear definition of what is, and
what is not, a ‘pet cat’. What follows are 
reasonable recommendations, based on 
scientific evidence and expert advice, appli -
cable to most cats presented to private 
practitioners. Differences in cat population
density, introduction of new cats, and 
exposure risk are dynamic variables that the
veterinarian must take into consideration
when recommending any vaccine for any cat.
It is advised that veterinarians reassess risk
factors for exposure to infectious disease at
each visit (at least once a year), as changes in
factors such as the health of the animal or its
lifestyle may dictate changes to vaccination
needs.
Table 2 summarizes vaccination recommen-
dations for household pet cats. 
Figure 2 Pet cats that
spend any time outdoors 
are at greater risk of
exposure to many infectious
diseases compared with
indoor-only pet cats. 
Images courtesy of Dr Terry
Curtis (a), Dr Margie Scherk (b)









once a year, 
as changes in
the health of






 at Wissenschaftliche Bibliothek on March 10, 2015jfm.sagepub.comDownloaded from 
Additional considerations when
vaccinating household pet cats 
Because vaccination requirements and risk of
exposure to infectious agents vary among
household pet cats, individual vaccination
protocols will vary. The following recommen-
dations address some alternative situations
and offer insights on vaccination of pet cats
using non-core vaccines.
< Vaccination of pet cats in indoor/outdoor
households Cats housed exclusively indoors
generally do not require vaccination beyond
the aforementioned vaccines (ie, FPV, FHV-1,
FCV ± FeLV, rabies). However, in multiple-cat
households where some cats are housed
exclusively indoors, yet other cats are
permitted outside unmonitored, the entire
household may be at risk of exposure to
additional agents. Veterinarians should
consider recommending vaccination of the
entire household for selected diseases (eg, FeLV
± rabies) if exposure risk is deemed significant.
Pet cats that spend most (or all) of their
lives outdoors are at greater risk of exposure
to most infectious diseases compared with
predominantly indoor pet cats (Figure 2).
790 JFMS CLINICAL PRACTICE
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Offsetting this is the natural boosting of
immunity they may receive if they are
exposed to infectious agents. Among outdoor
adult cats, exposure risk for rabies, FeLV and
FIV is generally higher than for indoor cats.
In addition to the conventional vaccines
recommended in Table 2, FIV vaccination
could be considered for outdoor cats. (See
accompanying Disease Information Fact
Sheet on FIV – details on page 799.)
< Vaccination of pet cats entering boarding
facilities Although, in general, healthy adult
cats only require boosters to FPV, FHV-1, FCV
vaccines every 3 years, an additional booster
7–10 days prior to boarding may be
warranted (and may be required by some
catteries), particularly if the cat has not been
vaccinated in the previous year. Boarding
may be stressful for a cat and also, depending
on the cattery and the situation at the time,
may lead to exposure to infectious agents.
However, disease control measures vary
between facilities, with many providing
individual housing, sneeze barriers and good
hygiene, whereas others permit co-mingling


















dose as early as







Revaccinate 1 year after primary series;
thereafter, boost every 3 years, lifelong
Modified-live and inactivated vaccines 
are available for parenteral administration; 
in some countries intranasal vaccines 
are also available. 
For cats going into boarding or another
high exposure, stressful situation, a
booster 7–10 days prior to boarding may
be warranted, particularly if the cat has













Administer a single dose 1 year following
administration of the initial two-dose series.
Results of several studies indicate that FeLV
vaccine-induced immunity persists for at
least 12 months following vaccination.12–14
Thereafter, the Advisory Panel recommends
revaccination every 2 years for cats at low
risk of infection and annually for cats at
higher risk. A study by Jirjis et al suggests
that DOI induced by some FeLV vaccines
may last for at least 2 years.15 Another
guidelines group (European Advisory Board
on Cat Diseases) recommends that for cats
older than 3–4 years of age, a booster
vaccination every 2–3 years is sufficient.16
(see accompanying Disease Information
Fact Sheet on FeLV – details on page 799)
Test first to verify FeLV antigen-negative 
status.
As kittens are more susceptible to 
progressive FeLV infection,17 and as the
eventual environment into which a kitten
will go can rarely be predicted with 
certainty, the Advisory Panel
recommends routine FeLV vaccination 
for all kittens up to and including 1 year
of age.18 At-risk adult cats should






mandated or in an
endemic region
Administer a single
dose at not less
than 12 weeks/
3 months of age
Administer a single
dose
Administer a single dose 1 year following
the initial dose; then repeat annually (or
every 3 years if using a vaccine licensed
for this interval)
Where rabies vaccination is required, the
frequency of vaccination may differ from
these recommendations based on local
statutes or requirements. Veterinarians
should be familiar with, and adhere to,
local requirements
NB Unless otherwise stipulated, all parenteral vaccines should be administered by the subcutaneous route
Table 2 Recommendations for vaccination of household pet cats
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transmission. In the event that kittens must
enter a boarding facility, it is recommended
that they should have received at least two
doses of FPV, FHV-1, FCV vaccine, with the
last dose 7–10 days prior to entry. In addition,
it is strongly recommended that kittens be
isolated from the general population of adult
cats at all times while boarding.  
< Vaccination during pregnancy and
lactation Vaccination of pregnant or lactating
cats is generally not recommended. Whenever
possible, queens should be vaccinated before
breeding. Vaccines are not evaluated for use in
pregnant queens unless specifically stated on
the label. However, the benefits of vaccination
may outweigh the risks in endemic disease
situations. Modified-live FPV vaccines should
not be administered to pregnant queens as
this has been associated with cerebellar
hypoplasia in the kittens.19 (For a more
comprehensive discussion, see
‘Recommendations for vaccination of cats
housed in breeding catteries’, page 793.)
< Overdue for vaccination If the cat has 
been vaccinated previously and is overdue 
for revaccination (irrespective of the interval),
generally a single vaccination is all that is
required. If prior vaccination status is unknown,
the cat should be treated as unvaccinated.
< Bordetella bronchiseptica, Chlamydophila
felis, FIP and FIV vaccination For
information on the use of these vaccines, 
see accompanying Disease Information Fact
Sheets (details on page 799).
< Dermatophytosis vaccination At the time of
writing, a monovalent (Microsporum canis) and 
a multivalent (Microsporum and Trichophyton
species) inactivated product are licensed for the
prevention and treatment of dermatophytosis 
in cats in some countries in Europe. None are
currently available in the USA or Canada.
Limited evidence exists to support the safe use
of these products as part of a comprehensive
treatment protocol in cats with proven infection,
but little evidence is available to support their
use for prevention of infection.20,21
Recommendations for vaccination
of shelter-housed cats
Generally, shelter-housed cats (Figure 3) can
be considered to be at especially high risk 
of exposure to infectious disease. Endemic
disease, high rates of turnover, stress and 
sustained exposure are contributing factors.
Vaccination in shelters should be limited to
those diseases that are likely to be transmitted
within the shelter itself. For diseases of con-
cern in shelters (notably FPV and upper respi-
ratory infections), vaccines may be indicated
at an earlier age, and be administered at short-
er intervals compared with schedules for 
pet cats. Rapid onset of protection is critical;
therefore, administration of FPV, FHV-1, FCV
vaccines should be considered for all cats at
the time of (or ideally, before) intake. 
Table 3 summarizes vaccination recommen-
dations for shelter-housed cats.
Additional considerations when
vaccinating shelter-housed cats
< Bordetella bronchiseptica and
Chlamydophila felis vaccination The benefit
of routine vaccination of shelter-housed cats
against these disease agents is limited. The
association between B bronchiseptica isolation
and disease in shelters is inconsistent31–34 and
C felis is not commonly isolated from shelter
cats with upper respiratory infection.31 These
vaccines should only be considered if the
pathogens have been demonstrated as a
current problem by laboratory diagnostics. 
B bronchiseptica vaccination should also be
used where there is potential direct or
indirect contact between cats and dogs on 
the same site, and the dogs have a recent or
current history of infectious respiratory
disease. 
< FIV and FIP vaccination Vaccination of
shelter-housed cats against these agents is not
generally recommended. 
< Dermatophytosis vaccination See
comments in the household pet cats section.
Figure 3 Generally, cats 
in shelters, whether
individually (a) or group (b)
housed, are at especially
high risk of exposure to
infectious disease. Images
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dose at intake or,
where possible, at




dose as early as













Recent studies show that ML SC vaccination may provide better 
protection in the face of MDA than inactivated vaccines do, and may
protect against illness even when cats are placed in a contaminated
environment soon after vaccination.22,23
ML injectable or IN vaccines containing FPV should not be given to 
kittens less than 4 weeks of age due to the risk of cerebellar hypoplasia19
or clinical panleukopenia (see Appendix 1 [Shelter FAQs] ‘Are there 
special considerations for vaccinating and housing very young kittens 
in shelters?’, page 803). 
For pregnant queens, risk of exposure versus risk of vaccination should 
be balanced (see Appendix 1 [Shelter FAQs] ‘Should pregnant queens in
shelters be vaccinated?’, page 804).
Inactivated multivalent calicivirus vaccines exist and may provide broader
cross-protection against calicivirus infection than single strain vaccines.24,25
Calicivirus may be more prevalent in shelters housing cats long term in
group settings;26,27 a multivalent vaccine may be preferable in this 
context. If FCV disease occurs in fully vaccinated cats housed in groups,




(IN FHV-1, FCV) 
Modified-live
If IN* vaccination is
used for control of
respiratory viruses,
all shelter cats over
4–6 weeks of age
should
simultaneously
receive a SC ML




dose at intake or,
where possible, at
least 1 week prior
to shelter entry. 
In kittens, 
administer the first
dose as early as













IN vaccination may result in onset of protection as early as 4–6 days 
post-inoculation.6,28 
Study results have been mixed* regarding reduction in risk for upper
respiratory tract infection in shelters from IN vaccination.29,30 
When using IN vaccination, use only products licensed and approved for
administration by this route. 
Transient, mild signs of upper respiratory infection may develop following


























Necessary for all cats where legally mandated or in an endemic region.
For shelters adopting out virtually all cats, or where the length of stay is
commonly months or longer, rabies vaccine should be administered on
intake. For shelters with shorter lengths of stay or where not all cats are
adopted, rabies vaccination at the time of release is acceptable. 
If local regulations prohibit issuance of a rabies certificate for vaccines
administered at the shelter, cats should receive a rabies vaccination from 






dose of vaccine at




for kittens is used,
vaccinate as early













Unlike group-housed cats, risk of FeLV transmission is very low for 
individually housed cats. 
FeLV vaccination is recommended for cats in long-term shelters or in
group-housing of unrelated cats. 
Vaccination is not a substitute for testing and segregation of infected cats
NB Unless otherwise stipulated, all parenteral vaccines should be administered by the subcutaneous (SC) route
*IN vaccination may provide protection against herpesvirus infection within 4–6 days, providing a hypothetical benefit in shelters.6,28 However, results
of IN vaccination for respiratory viruses in addition to parenteral vaccination in shelters are mixed, showing a modest reduction in upper respiratory
disease in one shelter29 but no difference in another.30 Although simultaneous use of IN and parenteral vaccination is not generally tested by
manufacturers and licensed for such use, there was no evidence in either study of reduced efficacy of the parenteral vaccine due to concurrent IN
vaccine administration.29,30 No information on safety was reported in these studies; however, there was no significant increase in respiratory signs
within the first 7 days of administration in cats receiving the IN with the parenteral vaccine versus the parenteral vaccine alone, suggesting that
vaccine-induced respiratory signs were not a significant concern. ML = modified-live, IN = intranasal, MDA = maternally derived antibodies
Table 3 Recommendations for vaccination of shelter-housed cats
For diseases of concern in shelters, vaccines may be indicated at an earlier age
and administered at shorter intervals compared with schedules for pet cats.
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Recommendations for
vaccination of cats in
trap–neuter–return programs
Most community cats (Figure 4, ie, free-roam-
ing unowned feral and stray cats) lack protec-
tive antibody titers against FPV, FHV-1 and
rabies.9,35 In one study, the vast majority of
feral cats vaccinated once at the time of TNR
surgery developed protective antibody titers
against FPV and FCV by the time they were
re-trapped for testing 2–3 months later,
regardless of whether inactivated or modi-
fied-live vaccines were used.35 In contrast,
only inactivated vaccines resulted in a high
rate of protective antibodies against FHV-1.35
In the same study, nearly all cats developed
high antibody titers against rabies after a 
single dose of inactivated rabies vaccine.35
Vaccine licensing studies have demonstrated
3–4 year DOI following a single vaccine
administered to laboratory kittens. This 
suggests that, while the first rabies vaccine
may only be recognized by regulatory agen-
cies as valid for a single year, it is likely that
vaccinated cats are protected for much longer. 
It is the recommendation of the Advisory
Panel that cats in TNR programs receive FPV,
FHV-1, FCV and rabies vaccines at the time of
surgery.
Recommendations for
vaccination of cats housed 
in breeding catteries
Breeding catteries are variable in size, popula-
tion and the nature of available facilities. The
cat population may number less than 10 indi-
viduals or more than 50. Cats of various ages
and life stages are typically present and many
catteries continue to house retired breeding
individuals that have been neutered. Some
also contain household pets that may or may
not have access to outdoors. The facilities may
be sophisticated enough to allow for segrega-
tion of subpopulations or all individuals may
be housed together. Generally, the medical
and vaccination history of the residents is well
known, but some diseases, such as upper res-
piratory tract disease, may be endemic. 
Vaccination programs should be limited to
those diseases that are relevant to the cattery
and should be determined by analysis of risk
factors. When assessing the level of disease
risk in catteries, factors to consider include:
< Rate of population turnover. 
< Population size and density. 
< Number of litters/year (Figure 5). 
< Presence of endemic disease. 
Transmission of infectious diseases is facili-
tated by group living, young kittens mixing
with older kittens and adults, contact during
mating, introduction of new cats, and move-
ment of cats into and out of the cattery 
(eg, queens going to other catteries for breed-
ing, return of previously sold cats, travel for cat
shows or other exhibitions). Catteries assessed
as low risk would be considered similar to pet
homes (Table 2), whereas catteries assessed as
high risk would be considered similar to shel-
ters (Table 3), pet stores, etc. In high-risk envi-
ronments, vaccines may be used at an earlier
age than in pet cats, particularly for control of
endemic upper respiratory tract disease.
In general, vaccination may be started at an
earlier age than in the pet cat population and
revaccination intervals may be shortened.
Breeders should be encouraged to work with
a veterinarian to develop a comprehensive
wellness program that includes appropriate
vaccinations for their specific situation.
Vaccination records should be kept for each
individual in the cattery that include all 
relevant information (eg, antigen, brand, date,
vaccination site, adverse events, etc).
Management and husbandry have an impor-
tant impact on the health of individual cats in
catteries. Relevant references and resources












Figure 4 Community cats in TNR programs (a,b) should receive FPV, FHV-1, FCV and rabies
vaccines at the time of surgery. Images courtesy of International Cat Care
Figure 5 The number of
litters produced per year 
in a breeding cattery is one
of the key factors in
determining the level of
disease risk, and devising 
an appropriate vaccination
program. Courtesy of 
Betsy Gaither
ba
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Table 4 summarizes vaccination recommen-
dations for cats in breeding catteries.
Additional considerations when
vaccinating cats in breeding catteries
< FeLV and FIV vaccination Vaccination of
cats in breeding catteries against these agents
is not generally recommended. Vaccinate if
necessary by analyzing risk, as for household
pet cats and kittens (Table 2). The retrovirus
status of all cats should be known:
vaccination is not a substitute for testing and
isolation. Vaccination may be unnecessary if a
good testing program is in place and no cats
have access to the outdoors.13 If queens are
routinely sent to another cattery for breeding,
vaccination of breeding queens may be
considered.
< Rabies vaccination Cats in breeding
catteries in the USA must be vaccinated
against rabies according to state regulations.
Elsewhere, vaccination against rabies is not
generally recommended. Vaccinate if
necessary by analyzing risk, as for household
pet cats and kittens (Table 2).
< Bordetella bronchiseptica and
Chlamydophila felis vaccination The benefit
of routine vaccination of cats in breeding
catteries against these disease agents is
limited. These vaccines should only be
considered if the pathogens have been
demonstrated as a current problem by
laboratory diagnostics. When used, the
primary series should be administered
according to the manufacturer’s instructions,
with annual revaccination if the problem
remains endemic. In some countries, the
manufacturer states that Bordetella
vaccination is considered safe for pregnant
queens. However, in other countries,
datasheets advise that the vaccine should 
not be used in pregnant or lactating queens 
or in kittens less than 1 month of age.
< FIP vaccination Vaccination of cats in
breeding catteries against FIP is generally not
recommended as there is insufficient evidence
that the vaccine induces clinically relevant
protection. (See accompanying Disease
Information Fact Sheet – details on page 799.)
< Dermatophytosis vaccination See earlier
comments in the household pet cats section
(page 791).
Vaccine adverse events
Although the administration of biological
products can never be entirely free of risk, in
general currently available feline vaccines have
an excellent safety record. It is important to
report any known or suspected negative events
associated with vaccination, recognizing that a
temporal relationship between an event and
vaccine administration does not necessarily
imply causality. In the United States, veterinar-
ians are requested to contact the manufacturer
(Veterinary Technical Services) of the vaccine(s)
considered to be involved; veterinarians may
also report known or suspected adverse events
directly to the US Department of Agriculture.
In other countries procedures may vary, but, 
in general, veterinarians should contact the
manufacturer and notify the appropriate regu-
latory agency to report a vaccine adverse event
(eg, the Canadian Centre for Veterinary
Biologics [Canada]; the Veterinary Medicines
Directorate [UK]; the European Medicines








As for household pet cats
(Table 2)
High risk
Consider FHV-1 and FCV
vaccination every 1–2 years.
Consider ML vaccines for
rapid onset of protection.





If FCV disease occurs in fully
vaccinated cats housed in
groups, changing to a
product with a different
vaccine strain(s) may be of
benefit27
Low risk
As for household pet cats (Table 2)
High risk
ML injectable vaccine starting at 4–6 weeks,
boosters every 2–3 weeks until 16–20 weeks7–11
Endemic upper respiratory tract disease
IN vaccination (FHV-1, FCV only) starting at 3–4
weeks for rapid onset of protection,6 followed by
injectable ML FPV, FHV-1, FCV every 2–3 weeks
until 16–20 weeks. The efficacy of administering 
one or two drops of IN vaccine per kitten instead 
of a full dose is unknown and is not recommended.
Avoid ML IN or injectable vaccines containing FPV 
in kittens less than 4 weeks of age due to the risk 
of cerebellar hypoplasia19 or clinical panleukopenia.
Kittens can be vaccinated around or at the time of
spay/neuter surgery without compromising 
serologic response8
Whenever possible, queens should be
vaccinated before breeding. However,
benefits of vaccination may outweigh
risks in endemic disease situations.
Though not generally licensed for such
use, vaccines administered early in 
pregnancy may protect the queen and
provide enough MDA to protect kittens
during the first weeks of life.38 No
increase in abortions or stillbirths was
documented in one study using an
inactivated vaccine in this way.39
ML injectable or IN vaccines containing
FPV should not be given to kittens less
than 4 weeks of age due to the risk of
cerebellar hypoplasia19 or clinical
panleukopenia. For pregnant queens, 
risk of exposure versus risk of
vaccination should be balanced.
Queens may be vaccinated during
lactation if the benefits outweigh the risks
NB Unless otherwise stipulated, all parenteral vaccines should be administered by the subcutaneous route
ML = modified-live, IN = intranasal, MDA = maternally derived antibodies
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Agency [EU]. (See Appendix 1 [Adverse Event
FAQs] on page 805 for specific reporting forms
and instructions.)
The most commonly reported vaccine reac-
tions are lethargy, anorexia and fever for a few
days after vaccination, or local inflammation at
the site of injection.4,42,43 Rarely anaphylaxis is
seen. Because vaccines are biologically active
products, occasional adverse reactions associat-
ed with vaccination are inevitable. It should be
recognized, however, that establishing causali-
ty is often difficult, especially if the suspected
reaction is delayed (days or weeks).43
Prevalence and type of adverse reactions
Although post-vaccinal adverse events in cats
are considered rare, the true prevalence is
likely to be underestimated due to under-
reporting by both veterinarians and owners.44
In the most substantial survey to date, adverse
reactions were reported for all cats presented
to Banfield Pet Hospitals in the United States
between 2002 and 2005.4 During this period,
more than 1.25 million doses of various vac-
cines were administered to nearly 0.5 million
cats. Adverse reactions within 30 days of vac-
cination were reported at a rate of 51.6/10,000
cats vaccinated (0.52%), with 92% of these
reactions occurring within the first 3 days.
Clinical signs described for 1699 of 2560 cats
with vaccination-associated adverse events
included lethargy (± pyrexia) in 54%, local
pain or swelling at the vaccine site (25%),
vomiting (10%), facial or periorbital edema
(6%) and generalized pruritus (2%). Death
was reported in four cats, and in at least two
of these it was attributed to anaphylaxis. 
Although the vaccines used were predomi-
nantly from one manufacturer, no vaccine type
was found to be significantly more likely to
cause local reactions. Administration of multi-
valent FPV, FHV-1, FCV and Chlamydophila
vaccines was significantly more likely to be
associated with lethargy (± pyrexia) than
administration of vaccines without the
Chlamydophila component. The risk of an
adverse reaction was greatest in cats around 1
year of age and/or increased as the number of
vaccines administered concurrently increased.4
In another extensive study specifically investi-
gating local post-vaccine reactions, a preva-
lence of 0.23% was reported.45 Previous large
FeLV and FIV
The retrovirus status of all cats should be known and this is
important if administration of FeLV or FIV vaccines is being 
considered.18 There is no recognized clinical
benefit in administering vaccine against the
retrovirus a cat is infected with, nor are there
any known harmful effects. However, when the
true retrovirus status of a vaccinated and
infected cat eventually becomes known, not
having known the cat’s status before vaccina-
tion could result in questions about failure to
recommend testing before vaccination and
vaccine efficacy. 
Use of serology 
The use of serology (serum antibody titers) 
to assess protective immunity has been
reviewed.1,40,41 It is important to be aware that a
variety of methods (immunofluorescence assay,
ELISA, virus neutralization, haemagglutination
inhibition, etc) are utilized to determine titers.
The methodology used may not be reported
with the test results. Titer results in individual
cats determined at the same point in time,
therefore, may vary depending on the method-
ology used. When electing to submit serum for
antibody titers, it needs to be appreciated that
a ‘positive’ antibody titer result obtained on one day is not nec-
essarily predictive of a ‘positive’ titer at any point in the future. 
In general, cats having a ‘positive’ antibody titer against FPV
are immune. In fact, the protective immunity that develops fol-
lowing FPV vaccination is expected to be sustained for several
years. By contrast, serum antibody titers for FHV-1 and FCV may
not necessarily correlate well with protective
immunity and should not be used to predict
protection in the future. Antibody titers to FeLV
and FIV do not correlate with immunity and
should not be used to determine the need for
vaccination. Although feline rabies titers can 
be determined (by a certificated laboratory) in
individual animals, a rabies titer is only an indi-
cation of serological response to vaccination.
Rabies titers are not recognized as an index of
immunity.
In addition, the absence of significant levels
of antibody (a ‘negative’ titer) is not necessari-
ly an indication of susceptibility. For example, 
a previously vaccinated cat may, over time,
lose antibody. Immunologic ‘memory’, how -
ever, may prevail. In the event this individual is
exposed to a virulent virus, a rapid anamnestic
and protective response could result. In some
diseases (eg, FHV-1), cell-mediated immunity is
important and a cat may be immune even
though no antibodies are detectable.
Because antibody titers may not reliably 
correlate with, or predict, the degree of protec-
tion or susceptibility for an individual cat, the Advisory Panel 
recommends employing defined revaccination intervals rather
than measuring antibody titers to assure protection. 
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studies have suggested adverse vaccine reac-
tion rates of around 1–3%,46–48 but some varia-
tion in prevalence can be expected with the use
of different products, administration of multi-
ple vaccines at the same appointment, and 
surveillance methods. 
Hypersensitivity reactions
Anaphylaxis and allergic reactions
Anaphylaxis is perhaps the best characterized
immune-mediated hypersensitivity (type I)
reaction to vaccination, but it is rare (approxi-
mately 1–5/10,000 vaccines).4,46 In cats it may
manifest as vomiting, diarrhea, respiratory
distress, facial or generalized pruritus, facial
swelling and collapse.1,43,49
A careful risk assessment is needed when
considering the revaccination of cats with a
history of anaphylaxis. In cats that have 
experienced an allergic reaction with true 
anaphylaxis, revaccination should usually be
avoided. Vaccine excipients (inactive ingredi-
ents) are thought to cause most type I hyper-
sensitivity reactions.4 Hence, where revaccina-
tion is considered necessary, using a different
vaccine formulation and premedicating with
an antihistamine and glucocorticoids 20–30
mins prior to vaccine administration is recom-
mended, followed by close observation of the
patient for several hours.1,4
Depending on geographic location, the
requirement to vaccinate cats for rabies may
take precedence over medical considerations.
Veterinarians are urged to contact the appro-
priate authorities to determine what the local
status is when concerns arise and whether the
individual may be excused from vaccination.
(See also 2006 Guidelines, Appendix 1:
Certificate of Exemption from Rabies
Vaccination – details on page 786.)
Other reactions
While other forms of hypersensitivity reac-
tions (types II, III and IV) almost certainly
occur in cats after vaccination, these are rarely
documented. Some forms of local reaction
probably reflect type IV reactions. Poly -
arthritis is occasionally seen after FCV vacci-
nation. Rarely it may represent a form of type
III reaction, but it is mainly due to co-infection
with field virus or vaccine virus itself.50,51
(See Appendix 1 [General FAQs] ‘What is the
cause of lameness occasionally seen after FCV
vaccination?’, page 802.)
Update on feline injection-site sarcomas
(FISS)
Vaccine-associated sarcoma was first recog-
nized as an issue in cats in the early 1990s.
While initial studies suggested a risk of sarco-
ma development in around 2/10,000 doses of
vaccine administered,52 which increased to
13–36/10,000 doses in other studies,53–55 cur-
rent estimates based on larger epidemiologic
studies (published between 2002 and
20074,45,56) suggest that the risk of sarcoma
development following vaccination is actually
very low (probably well below 1/10,000 doses
of vaccine).4,45
Although initial reports linked develop-
ment of sarcomas at vaccination sites with the
use of inactivated rabies57 or FeLV vaccines,52
and aluminum-based adjuvants, more recent
studies found no relationship between vac-
cine type, brand or use of inactivated versus
modified-live vaccines and the risk of subse-
quent sarcoma formation.56,58,59 The impact of
using the canarypox-vectored rabies vaccine
is still unclear. One retrospective study of
histo pathology samples showed no reduction
in the prevalence of FISS after the introduction
of this vaccine; however, the types of vaccine
used were not reported.58 In a recently pub-
lished case control study it was suggested that
there may be a lower risk of inducing sarco-
mas with this vaccine than with other rabies
vaccines.59 Many of these studies have also
clearly shown that injections other than vac-
cines also have the ability to induce sarcoma
formation.
No studies have been published that define




Based on our current
understanding of










interaction of mul -
tiple extrinsic (eg, 
frequency and num-
Suggested approach to the treatment of anaphylaxis
< Place intravenous catheter 
< Administer epinephrine (adrenaline): 0.1 ml of a 1:1000 dilution IV 
< Administer 20–30 ml/kg  balanced isotonic crystalloid by slow infusion
over 10 mins
< Provide oxygen 
< Administer an H1-blocker: eg, diphenhydramine, 2 mg/kg IM or IV
< Administer soluble glucocorticoid: eg, methylprednisolone sodium
succinate, 30 mg/kg IV 
Figure 6 While vaccines 
are not uniquely implicated
in sarcoma formation, there
are certain actions that 
can be taken to reduce 
the risk of FISS, as
summarized in Table 5.
Courtesy of Albert Lloret
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ber of vaccines administered over time, com-
position of the injected product, etc) and
intrinsic factors (eg, genetic predisposition,
tissue response following injection, etc). The
presumed relationship between types of vac-
cine, inflammation at the site of vacci nation61
and subsequent FISS development appears
complex at best and, if involved, is likely only
one among many factors that contribute to
FISS development.
Table 5 provides a brief review of consider-
ations and management options for the reduc-
tion of FISS risk, taken from current publica-
tions. None of these suggestions are known to
prevent or cure FISS.
When considering vaccine type, the
Advisory Panel recommends that the follow-
ing be taken into consideration. Recent stud-
ies demonstrate that all vaccines carry some
risk of inducing FISS, as do at least some other
injectable products. Although current infor-
mation as outlined above does not clearly
show differences in risk of FISS development
between modified-live and inactivated vac-
cines, some Advisory Panel members consid-
er that, on balance, risk might be mitigated 
by the use of modified-live vaccines. There are
Action suggested Objective Comments
Recommend/administer vaccines 
on the basis of reasonable risk for 
exposure to the infectious pathogen
To avoid unnecessary 
vaccination of cats
Studies have suggested that the risk of FISS increases as the number of 
vaccines received over time increases37,62–64
Administer vaccines only as
frequently as needed to provide
protective immunity
To avoid unnecessary 
vaccination of cats
Administer FPV, FHV-1, FCV no more often than every 3 years, 
except in high-risk situations1,63
Administer parenteral feline 
vaccines by the SC route only
To facilitate early detection 
of tumor
Vaccine administered by the IM route does not reduce the risk of
tumorigenesis and may delay the detection of a mass located within
muscle (vs skin). It is recommended that all parenteral vaccines be
administered by the SC route65
Use recommended vaccination sites To facilitate complete tumor
removal by limb amputation in
the event that FISS develops
See vaccination site recommendations on page 798
Consider vaccine type To reduce the risk of chronic
local inflammation at the
injection site, which may 
occur in some cats56 
The role of adjuvants (including those containing aluminum) and local
inflammation in the pathogenesis of FISS is not clear.52,57,61,64–68 Both
adjuvanted and non-adjuvanted vaccines induce local inflammation,
although the magnitude and type of inflammation varies among vaccines,
adjuvants and individual cats. However, some authors recommend
considering non-adjuvanted vaccines to try to reduce local inflammation61
Biopsy of a post-vaccination ‘lump’:
the ‘3-2-1 rule’
To establish the presence or
absence of malignant tumor 
formation as early as possible
Perform an incisional (vs excisional) biopsy if a lump:
(a) persists for 3 months or longer after injection; or,
(b) ever becomes larger than 2 cm in diameter; or, 
(c) continues to increase in size 1 month after injection58
Perform additional assessment 
pre-surgically when FISS is
confirmed
To evaluate the feasibility of
attempting definitive treatment
Tumors are locally aggressive; thoracic metastasis occurs in over 25% 
of cases. Thorough pre-surgical evaluation of individual cases, including
physical and laboratory assessment, thoracic radiography and other
imaging as indicated, is recommended prior to surgical excision63,69,70
Remove tumor surgically To completely excise the tumor Surgery offers the best opportunity for cure. Radical surgery is usually
required to prevent recurrence. Local excision (‘lumpectomy’) of FISS is not
recommended. In addition to surgery, radiation therapy and/or chemotherapy
may be recommended based on consultation with an oncologist71–75
FISS = feline injection-site sarcoma, SC = subcutaneous, IM = intramuscular




To avoid the risk of fetal/
neonatal infection with
ML FPV
ML FPV may replicate in
cerebellar tissue of fetal and/or
neonatal kittens, leading to
clinical signs associated with
cerebellar hypoplasia19
Vaccination of cats
known to be retrovirus
positive
To avoid unlikely, but 
potential consequences
of exposing an immune-
suppressed cat to ML,
replicating vaccine virus
The risks associated with 
administering ML vaccine virus







known to be present
To avoid the risk of
accidental or inadvertent
oral/nasal exposure to
ML FHV-1 and FCV
vaccines
ML FHV-1 and FCV vaccine virus,
if inadvertently aerosolized or
inoculated by the oral or nasal
routes, may cause upper
respiratory signs associated 
with vaccine virus replication 
on mucosal surfaces
Rabies vaccine: when
3-year DOI is indicated
or required
To provide licensed 
3-year DOI
The only rabies vaccines currently
licensed to provide 3-year DOI
are inactivated vaccines
ML = modified-live, DOI = duration of immunity
Table 6 Indications for the use of inactivated vaccines in cats
also other factors that may influence the
choice of live versus inactivated vaccines 
(see Table 6 and Appendix 1 [General FAQs],
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Post-vaccination monitoring
The Advisory Panel recommends that clini-
cians and their staff instruct clients to monitor
the vaccine site for swelling or lumps in order
to detect potential sarcomas while they may
still be removed successfully. Biopsy of any
mass present is warranted if it (a) remains pres-
ent 3 months after vaccination; (b) is larger than
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page 803). Overall, however, the Advisory
Panel concluded that, at the current time,
there is insufficient information to make
definitive recommendations to use particular
vaccine types to reduce the risk of FISS.
There is a lack of clinical information to make evidence-based
vaccine site recommendations. The majority of safety and effica-
cy data comes from licensing studies in which vaccines are
administered subcutaneously in the interscapular region. Due to
concerns of potential sarcoma development, practitioners may
consider giving vaccines in other locations. Current research
indicates that radical surgical resection of injection-site sarco-
mas, including margins of 5 cm when possible, is associated
with the highest response rate and long-term survival.75 A 2009
paper reported an increase in lateral abdominal injection-site
sarcomas since the publication of the Vaccine-Associated Feline
Sarcoma Task Force vaccination recommendations in 1996.76
The Advisory Panel recommends, as in the 2006 Guidelines,
that veterinarians administer:
< FPV, FHV-1, FCV vaccines below the right elbow (Figure 7).
< FeLV vaccines below the left stifle (Figure 8).
< Rabies vaccines below the right stifle (Figure 9).
Vaccines should be administered as low on the leg as possi-
ble. Caution is warranted when vaccinating cats resting in a
crouched position as this may result in inadvertent injection of
the skin fold of the flank. Veterinarians should note that data on
the safety and efficacy of administering vaccines in very distal
limb locations are lacking. Figure 10 shows recommended 
vaccination sites, as well as sites to avoid.
Vaccination site recommendations
Figure 7 Administration of FPV, FHV-1, FCV vaccine subcutaneously below
the right elbow. Courtesy of Dr Susan Little 
Figure 10 Regions indicated in green are recommended. Those in red are
key sites that should be avoided. Image ©iStockphoto.com/GlobalP
Figure 9 Administration of rabies vaccine subcutaneously below the right
stifle. Courtesy Dr Susan Little
Figure 8 Administration of FeLV vaccine subcutaneously below the left
stifle. Courtesy Dr Susan Little
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Abbreviations used in the Report and Disease Information
Fact Sheets
AAFP American Association of Feline Practitioners
ADE Antibody-dependent enhancement 
APHIS Animal and Plant Health Inspection Service 
CPV-2 Canine parvovirus type 2
CVB Center for Veterinary Biologics
DOI Duration of immunity 
ELISA Enzyme-linked immunosorbent assay
EMA European Medicines Agency
FCoV Feline coronavirus 
FCV Feline calicivirus
FECV Feline enteric coronavirus
FeLV Feline leukemia virus
FHV-1 Feline herpesvirus-1
FIP Feline infectious peritonitis
FIPV Feline infectious peritonitis virus
FISS Feline injection-site sarcoma
FIV Feline immunodeficiency virus
FPV Feline parvovirus 
FPV, FHV-1, FCV Three-way panleukopenia + herpesvirus 1 + calicivirus 
vaccine (often referred to in North America as FVRCP)
IA Inactivated [vaccine] (also known as killed)
IM Intramuscular
IN Intranasal 
ISFM International Society of Feline Medicine
IV Intravenous
MDA Maternally derived antibodies
ML Modified-live [vaccine] (also known as attenuated)
r When preceding a vaccine, denotes a recombinant vaccine
(eg, rRabies)
SARSS Suspected Adverse Reaction Surveillance Scheme 
SC Subcutaneous
TNR Trap–neuter–return
URD Upper respiratory tract disease
USDA United States Department of Agriculture
VMD Veterinary Medicines Directorate
VS-FCV Virulent systemic feline calicivirus
DISEASE INFORMATION
FACT SHEETS




< Feline leukemia virus
< Feline immunodeficiency virus





< A brief review of the immune
response to vaccination
PET OWNER GUIDE 
(APPENDIX 2)
< Vaccinations for Your Cat
2 cm in diameter; or (c) is increasing in size 
1 month after vaccination (the ‘3-2-1 rule’ –
see Table 5). It is recommended that multiple
needle biopsies or an incisional wedge biopsy
are obtained to reduce the risk of harvesting
non-representative biopsy material and to min-
imize the risk of tracking tumor cells outside of
the future surgical field.
Legal considerations associated
with vaccination
Veterinarians in most countries are permitted
to use professional judgment in the selection
and use of licensed vaccines. Reference to these
Guidelines, therefore, is appropriate when
developing vaccination protocols for individ-
ual patients even though the guidance may
vary from the manufacturer’s label recommen-
dations or data sheet (eg, annual revaccination
vs triennial revaccination for core vaccines).
SUPPLEMENTARY FILES
Fact Sheets accompanying the 
2013 AAFP Feline Vaccination Advisory
Panel Report are available, 
together with the Pet Owner Guide
included in Appendix 2, at
http://jfms.com 
DOI: 10.1177/1098612X13495235
Rabies vaccination of cats
Where rabies vaccination of cats is required,
veterinarians may not have discretion to vary
from the manufacturer’s recommendations or
from requirements set forth by regulatory agen-
cies. Rabies vaccination requirements vary from
country to country and can vary significantly
within individual countries. In locations where
feline rabies vaccination is required by law, vet-
erinarians are obligated to be familiar with and
follow legal requirements when administering
rabies vaccines. Rabies vaccination recommen-
dations contained in these Guidelines do not
constitute vaccination requirements.
Medical record documentation 
of vaccination
At the time of vaccine administration, the fol-
lowing information should be recorded in the
patient’s permanent medical record:
< Vaccine(s) recommended for this patient.
< Date of vaccine administration.
< Identity (name, initials or code) of the
person administering the vaccine(s).
< Vaccine name, lot or serial number,
expiration date, and manufacturer of
vaccine(s) actually administered.
< Site and route of vaccine administration.
< Concurrent medications/therapy.
< Recommendations for future vaccinations.
Adverse events should be recorded in a
manner that will clearly alert all staff mem-
bers during future visits. Risks and benefits 
of vaccination should be discussed with the
owner so that they can make an informed
choice. Consent should be documented in 
the medical record to demonstrate that rele-
vant information was provided to the client
and that the client authorized the procedure.
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Ap p e n d i x  1 :  F r e q u e n t l y  a s k e d  q u e s t i o n s
General FAQs
< What is the optimal interval between vaccines? 
The minimum vaccination interval during the primary
series is 2 weeks, and the maximum recommended
interval is 4 weeks. Kittens presented 6 weeks or
longer following administration of the previous dose of
vaccine should receive at least two doses of vaccine, 
3–4 weeks apart. Although feline-specific data do not exist,
extrapolation from mice and humans suggests that a 3-week
interval is optimal for induction of memory T cells after
administration of a modified-live virus.1,2
< When should kittens be vaccinated?
The primary vaccination series in kittens is scheduled
between 6 and 16 weeks of age; vaccines should be
administered at an interval of 3–4 weeks. Under high-risk
circumstances (eg, in shelters and catteries with endemic
upper respiratory tract disease or panleukopenia risk),
vaccination may begin as early as 4–6 weeks of age and 
be repeated every 2–3 weeks until 16 weeks of age.
< How often should senior/geriatric cats be vaccinated?
How should I vaccinate cats with stable chronic disease? 
Whether older cats respond to vaccination in the same manner
as younger animals do is inadequately studied.3 In the absence
of data, the Advisory Panel recommends that healthy older
cats and those with chronic but stable disease conditions
receive vaccines in the same manner as younger adults. 
Less frequent vaccination is not advised due to inherent
immunosenescence. Further, more frequent immunization 
is not warranted in aged patients with a lifelong history of
immunization as data from other species suggests the memory
response remains intact throughout life and protective
immunity can be effectively maintained between boosts.4–6
< Should cats be vaccinated against rabies in areas 
where it is not required by law?
With the exception of Hawaii, cats in all of the states of 
the United States and cats in all countries or counties with
endemic rabies of any species should be vaccinated against
rabies, even if not required in that jurisdiction.
< Should I vaccinate immunocompromised cats? 
Patients with impaired immune responses, either due to infection
with FIV/FeLV or the use of immunosuppressive therapies, are at
increased risk of infection and may be candidates for vaccination.
Although there is limited feline-specific data, inactivated vaccines
are generally regarded as safer in patients with underlying
immunosuppression.7 Because immune responses are hampered
in immunocompromised patients, vaccination should ideally be
updated before immunosuppressive therapies are started.
Retrovirus-infected cats should not be vaccinated against the
retrovirus they are infected with.
< Should I vaccinate a kitten or cat with mild illness such
as chronic upper respiratory tract infection or diarrhea?
In kittens and cats with mild illness, vaccination 
does not need to be delayed if the patient is eating
and is not febrile. Should the illness be severe
enough to result in fever or significant inappetence,
vaccination should be delayed until these clinical
signs have resolved. If the interval between
vaccinations is delayed to greater than 6 weeks in primary
immunizations, the series should be re-initiated. (See
Shelter/Trap–Neuter–Return FAQs, pages 803–804, for
alternate recommendations for those settings.)
< Does it matter if the brand of vaccine used for
revaccination is different from the brand administered
previously?
While there are no studies comparing all vaccines for a
particular antigen (or group of antigens), based on the
available information the Advisory Panel believes that,
subsequent to the initial series, booster vaccinations do not
have to be of the same brand or vaccine type.
< Can a parenteral FPV, FHV-1, FCV vaccine that is 
meant to be administered via the subcutaneous route 
be administered intranasally?
No, nor should it be administered by any other mucosal route.
It will not stimulate an appropriate immune response and may
cause clinical disease.  
< What is the cause of lameness occasionally seen 
after FCV vaccination? 
In most cases, the lameness and pyrexia are due to
coincidental infection with field feline caliciviruses, though 
a small proportion may be due to vaccine virus itself.8,9
There is also some evidence of immune complex formation 
in the joints of cats infected with some strains of feline
calicivirus,10,11 but this is likely to be an uncommon cause 
of lameness after vaccination.
< How useful are the dermatophyte vaccines available 
in some European countries?
Dermatophyte vaccines have been marketed for years, but
scientific studies to prove their efficacy have been unsatisfactory.
Although some fungal vaccines may improve clinical signs
compared with placebo, there does not seem to be a difference
in infection rate between vaccinated and unvaccinated cats,
and reliable protection has not been documented.12,13
< Is it safe to mix and administer vaccine from one
manufacturer with vaccine from another manufacturer?
No. Only vaccines from the same manufacturer, and only
when stipulated on the product label/data sheet, may be
mixed in the same syringe and administered simultaneously.
Mixing vaccines from different manufacturers in the same
syringe at the same time carries significant risk that one
product (due to such factors as pH, osmolality, etc) may
rapidly and completely inactivate the immunogenic antigen 
in the other product, or even in both products.  
For this reason, it is recommended that when administering
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vaccine from two different manufacturers to the same patient
at the same appointment, separate inoculation sites should
be selected (eg, left side vs right side).
< How long is a vaccine stable for after being
reconstituted?
Vaccines should always be stored and handled according 
to the manufacturer’s instructions. After reconstitution, 
a vaccine should ideally be used immediately, but certainly
within 1 hour.
< Should the skin be disinfected before administering 
a vaccine?
No, the disinfectant could potentially inactivate modified-live
vaccine antigens. Cleaning and reusing of syringes is
discouraged for this reason, as well as the risk of
contamination. 
< Under what circumstances might an adjuvanted vaccine be
preferable to vaccines that do not contain added adjuvants?
There are a number of factors that may play a role in the
causation of FISS. Although initial reports linked development
of sarcomas at vaccination sites with the use of inactivated
vaccines and aluminum-based adjuvants, recent studies
show that all vaccines carry some risk of inducing FISS, 
as do at least some other injectable products.
Although current information does not clearly show
differences in risk of FISS development between modified-live
and inactivated vaccines, some Advisory Panel members feel
that risk might be mitigated by the use of modified-live
vaccines. However, overall the Advisory Panel concluded
that, at the current time, there is insufficient information to
make definitive recommendations to use particular vaccine
types to reduce the risk of FISS.  
There are indications for using an inactivated vaccine. The
risks and benefits should be discussed fully with the client.
Some examples of situations where this might be considered
are given in Table 6 of the Guidelines (page 797).
Shelter FAQS 
< Are there special considerations for vaccinating
and housing very young kittens in shelters?
It is preferable that kittens younger than 8 weeks 
of age be kept in foster care in clean homes.
Interference from MDA and lack of immune
competence has a negative impact on the ability of vaccines
to induce a protective immune response, and kittens placed
in shelters are at high risk of disease. If kittens younger 
than 8 weeks of age must be kept in shelters, they should 
be kept in areas isolated from the general population. 
When challenge dose is high and exposure is unavoidable,
FHV-1 and FCV intranasal or injectable vaccines may be
administered to kittens younger than 4–6 weeks of age. 
Some facilities administer one or two drops of intranasal
vaccine rather than the entire dose to each kitten. 
However, unless specifically stated on the label,
manufacturers have not evaluated the safety and 
efficacy of these vaccines when used in this manner, 
nor have such practices been independently evaluated. 
As such, use of a partial dose is not recommended. As in
older cats, signs of upper respiratory disease may be caused
by the vaccine. Nonetheless, in environments with endemic
upper respiratory disease where the risk of serious disease 
is high, the benefits of vaccinating in this manner may
outweigh the risks.  
Injectable or intranasal modified-live FPV vaccine may
cause cerebellar hypoplasia if administered to kittens prior 
to 4 weeks of age.14 Kittens in high-risk shelters should,
therefore, be vaccinated with a modified-live, injectable FPV
vaccine no earlier than 4–6 weeks of age. Vaccination should
be repeated every 2–3 weeks until 16–20 weeks of age. 
The shorter end of the inter-vaccination interval and earlier
age of first vaccination is appropriate when risk of infectious
disease is high, such as during an outbreak or in a known
contaminated environment. 
< Are there any special vaccine considerations 
for cats living long term (months or years) 
in shelters or sanctuaries?
Cats entering a long-term care facility (or any cat for
which a long-term shelter stay is anticipated) should
be vaccinated against rabies at the time of admission, unless
in a rabies-free region. FeLV vaccination is recommended for
cats that will be group housed, with the two vaccine primary
series ideally completed prior to placement in group housing.
Other non-core vaccines (ie, other than FPV, FHV-1, FCV)
should be considered as for household pet cats (see Table 2,
page 790), depending on risk profile. In the event that a cat
resides in the facility for a sufficiently long period to justify
booster vaccination, it is recommended that the same
schedule for revaccination be followed as is recommended
for pet cats. There is no indication for more frequent
vaccination in a long-term shelter facility with a stable
population. Cats in long-term care facilities are at increased
risk of calicivirus infections. Use of dual- or multi-strain
calicivirus vaccines in such facilities may be indicated. 
If FCV disease occurs in fully vaccinated cats, changing to 
a product with different vaccine strain(s) may be beneficial. 
< Are vaccine recommendations different for shelter cats
that are ill or injured? 
The great majority of shelter kittens and cats should be
vaccinated regardless of physical condition. If the cat’s
immune system is so weakened that a modified-live vaccine
will induce disease, exposure to the wide variety of infectious
pathogens present in most shelters will very likely be fatal. 
In general, if a cat cannot be safely vaccinated, it cannot
safely remain in an animal shelter except in strict isolation.
Cats that were injured or ill at the time of initial vaccination
should be revaccinated when healthy (no sooner than 
2 weeks after recovery). 
 at Wissenschaftliche Bibliothek on March 10, 2015jfm.sagepub.comDownloaded from 
804 JFMS CLINICAL PRACTICE
SPEC IAL  AR T ICLE / 2013 AAFP feline vaccination guidelines
< Should pregnant queens in shelters be vaccinated?
In general, vaccines are not licensed for use in pregnant
queens unless specifically stated on the product label. 
The use of modified-live vaccines in naive queens (ie, those
that have never been naturally exposed or vaccinated) during
pregnancy is particularly not recommended due to potential
adverse effects of FPV on developing fetuses.15 Nonetheless,
the likelihood of exposure to FPV is very high in many shelters,
and infection may result in the death of the mother as well as
her offspring. Therefore, the risks posed by modified-live
vaccination must be weighed against the risks of not
vaccinating (ie, maternal, fetal or neonatal infection and death).
When pregnant queens are being placed into shelters where
FPV exposure is likely, the Advisory Panel believes that the
overall benefits of modified-live FPV vaccination outweigh the
risks and are preferable in the shelter environment due to the
more rapid onset of protection. (See also Tables 3 and 6, on
pages 792 and 797, respectively.)
Vaccination against FHV-1 and FCV during pregnancy may
actually be beneficial for both mother and offspring, although
vaccines are not actually licensed for such use. Vaccines
administered early in pregnancy will not only protect the
mother, but may provide the offspring with higher levels of
MDA to protect them during the first few weeks of life.
Reduced morbidity and mortality from feline upper respiratory
infection was seen in kittens born to queens vaccinated with
an inactivated vaccine against FHV-1 and FCV during early
pregnancy, compared with offspring of queens not vaccinated
during pregnancy. There was no increase in abortions or
stillbirths associated with this practice.16
< Should previously vaccinated cats receive booster
vaccines at the time of shelter intake? 
In theory there is no reason to administer vaccines at the 
time of shelter admission if clear documentation of previous
vaccination within the timeframe recommended by these
Guidelines can be provided. An exception may be for the
respiratory viruses (FHV-1 and FCV). While protection
generally persists for 3 years,17 the degree of protection 
may wane over time. It may be helpful to revaccinate cats 
for FHV-1 and FCV if they have not received a vaccine in the
previous year. If there is any question about the vaccine
history, re-administering vaccines is preferable to reliance 
on uncertain records. 
< Should cats be vaccinated even if most of them are 
likely to be euthanased a few days after intake?
Yes, the primary reason to vaccinate cats in high-euthanasia
shelters is to prevent the development of endemic FPV
transmission. Protection against FPV develops in a high
proportion of cats within the first few days of vaccination 
(if there is no MDA interference). Vaccinating all cats at intake
is associated with a decreased risk of widespread FPV
outbreaks. 
< Should cats be vaccinated on intake even if they are
stray and, therefore, not the property of the shelter? 
Yes, stray cats should be vaccinated on intake. Many
community cats have no antibodies to protect against serious
illness;18,19 thus, the benefit of vaccination for population 
and individual health generally greatly outweighs the risk of
vaccination. To decrease risks associated with vaccination,
antigens and vaccines should be limited to those that present
a threat in a given shelter environment, and the clinical signs
and procedure for responding to an adverse vaccine reaction
should be prominently posted in all areas where vaccines are
administered. 
< Does performing spay/neuter surgery at the time 
of vaccination diminish immune responses?
Kittens sterilized a week before, a week after, or at the time 
of vaccination had similar antibody titers to kittens that were
vaccinated without surgery.20 Anesthesia and surgery do not
appear to impede serological responses to vaccination.
Trap–neuter–return FAQs
< Does the susceptibility of feral cats to 
common infectious diseases justify investment in
vaccination during trap–neuter–return programs?
The majority of feral cats admitted to one TNR
program lacked protective antibody titers against FPV, FHV-1
and rabies.18 The fact that some cats were seropositive
suggests that this population of cats was exposed to infectious
diseases and would benefit from immunization.
< Are feral cats that receive only a single vaccination
during the stressful experience of trapping and neutering
effectively immunized?
The vast majority of feral cats vaccinated at the time of
surgery developed protective antibody titers against FPV-1
and FCV by the time they were re-trapped for testing 2–3
months later, regardless of whether inactivated or modified-
live vaccines were used.18 In contrast, only
inactivated vaccines resulted in a high rate of
protective antibodies against FHV-1. Nearly all cats
developed high antibody titers against rabies after a
single dose of inactivated rabies vaccine.
< How long does a single rabies vaccine protect feral cats
against infection?
Although there are no reports of long-term evaluation in feral
cats, vaccine licensing studies have demonstrated 3–4 year
DOI following a single vaccine administered to laboratory
kittens. This suggests that while the first rabies vaccine may
only be recognized by regulatory agencies as valid for a
single year, it is likely that vaccinated cats are protected for
much longer. It is recommended that TNR programs offer
vaccine booster services for community cats.
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Adverse event FAQs
< What constitutes a vaccine adverse event and
what should I advise clients to watch for?
Vaccines are biological products that stimulate a
series of complex immune reactions that may
manifest transient side effects for up to 2 or 3 days
following vaccination. It is rare that these self-limiting side
effects escalate into serious adverse events. It is advisable to
inform clients that their cat may experience reduced appetite
or loss of appetite (lasting for two meals), pain at the injection
site, lethargy, reluctance to play/walk/run, or mild fever.
Treatment is seldom required.  
Clients should contact the veterinary practice should any
physical or behavioral effects worsen or continue beyond 
2–3 days. In the rare event that signs of systemic illness 
(such as vomiting, diarrhea, seizures, facial swelling, collapse
or difficulty breathing) develop, the owner should contact the
veterinary practice immediately.
< How do I report a vaccine adverse event?
The Advisory Panel strongly encourages veterinarians 
to report all known or suspected vaccine adverse events 
to the manufacturer and the appropriate regulatory agency
responsible for monitoring post-vaccinal adverse events 
(see details below).  
< Am I legally required to report vaccine adverse
events?
There is no legal mandate to report post-vaccinal
reactions in the USA, Canada or the European Union.  
< Am I legally liable for using a protocol based 
on my patient’s risk that differs from the one on the 
vaccine insert?
Continuous medical decision-making is an inherent aspect 
of veterinary medicine. There is no reason to believe that
decisions regarding vaccine selection and use will carry any
greater legal risk than the myriad other medical decisions
made in daily practice. Relative risk for utilizing these
Guidelines in developing patient vaccination protocols is
considered low. Some of the recommendations included 
in the 2013 AAFP Feline Vaccination Advisory Panel Report
will differ from the manufacturer recommendations published
in the product package insert/label. However, in most
countries, veterinarians in small animal practice have
considerable discretion in exercising their judgment 
relative to the selection and use of licensed veterinary
biological products within their professional practice. 
Rabies vaccination is the obvious exception – veterinarians
are required to follow local laws.      (Continued on page 806) 
Vaccine manufacturer 
Known or suspected adverse events should first be reported to the technical services staff of the vaccine manufacturer.
If multiple vaccines from different manufacturers were administered at the same time, reports should be submitted to
each manufacturer.  
Although vaccine manufacturers are required to maintain adverse event reports, they are not required to disclose that
information. They are under no obligation to offer compensation for diagnosis or treatment for alleged injury associated
with vaccine administration. 
Licensing/regulatory agencies 
< United States Veterinarians practicing within the United States may contact the United States Department of
Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS), Center for Veterinary Biologics (CVB):
– Web: http://www.aphis.usda.gov/animal_health/vet_biologics/vb_adverse_event.shtml
– Fax or mail: Download the PDF form at http://www.aphis.usda.gov/animal_health/vet_biologics/publications/
adverseeventreportform.pdf and FAX to (515) 337-6120 or MAIL to the CVB, 1920 Dayton Avenue, PO Box 844, Ames, 
Iowa 50010, USA 
– Telephone: (800) 752-6255
< Canada The Canadian Food Inspection Agency (CFIA) is responsible for licensing veterinary biologics, 
including veterinary vaccines that are manufactured and/or used in Canada. The licensing program operates under 
the Health of Animals Act and Regulations, and is administered by the Canadian Centre for Veterinary Biologics. 
Form CFIA/ACIA 2205 ‘Notification of Suspected Adverse Events to Veterinary Biologics’ may be found at:
http://inspection.gc.ca/english/for/pdf/c2205e.pdf
< European Union Oversight lies with the European Medicines Agency (EMA) and the national veterinary medicines
agencies. For example, in the United Kingdom, the Veterinary Medicines Directorate (VMD), an agency of the Department
for Environment, Food and Rural Affairs, is responsible for the Suspected Adverse Reaction Surveillance Scheme
(SARSS) for veterinary medicines.  
– Adverse reactions in animals in the UK should be reported at:
http://www.vmd.defra.gov.uk/adversereactionreporting/default.aspx
– Suspected human reactions to veterinary medicines in the UK should be reported at:
http://www.vmd.defra.gov.uk/adversereactionreporting/default.aspx 
Or contact the VMD at Freepost KT4503, Woodham Lane, New Haw, Addlestone, Surrey, KT15 3BR, UK. 
Telephone: 01932 338427 Fax: 01932 336618
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Veterinarians may be held liable for injury or death caused
by administration of a vaccine or any other medication.
Effective client communication is the best way to avoid 
legal consequences. Communication of risk and benefit
information to clients should be in direct and simple terms.
With respect to documentation, practitioners should
determine what best suits their practice and their level of risk
tolerance. For more information on informed consent (legal
considerations), Certificate of Exemption from Rabies
Vaccination, or vaccination documentation, please refer 
to the 2006 Guidelines (see box on page 786).
< What do I do if a patient has had a previous 
vaccine adverse event? 
Refer to page 796 for recommendations regarding the
approach to anaphylaxis and allergic reactions.
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There is a lack of clinical information to make evidence-based
vaccine site recommendations. The majority of safety and effica-
cy data comes from licensing studies in which vaccines are
administered subcutaneously in the interscapular region. Due to
concerns of potential sarcoma development, practitioners may
consider giving vaccines in other locations. Current research
indicates that radical surgical resection of injection-site sarco-
mas, including margins of 5 cm when possible, is associated
with the highest response rate and long-term survival.75 A 2009
paper reported an increase in lateral abdominal injection-site
sarcomas since the publication of the Vaccine-Associated Feline
Sarcoma Task Force vaccination recommendations in 1996.76
The Advisory Panel recommends, as in the 2006 Guidelines,
that veterinarians administer:
< FPV, FHV-1, FCV vaccines below the right elbow (Figure 7).
< FeLV vaccines below the left stifle (Figure 8).
< Rabies vaccines below the right stifle (Figure 9).
Vaccines should be administered as low on the leg as possi-
ble. Caution is warranted when vaccinating cats resting in a
crouched position as this may result in inadvertent injection of
the skin fold of the flank. Veterinarians should note that data on
the safety and efficacy of administering vaccines in very distal
limb locations are lacking. Figure 10 shows recommended 
vaccination sites, as well as sites to avoid.
Vaccination site recommendations
Figure 7 Administration of FPV, FHV-1, FCV vaccine subcutaneously below
the right elbow. Courtesy of Dr Susan Little 
Figure 10 Regions indicated in green are recommended. Those in red are
key sites that should be avoided. Image ©iStockphoto.com/GlobalP
Figure 9 Administration of rabies vaccine subcutaneously below the right
stifle. Courtesy Dr Susan Little
Figure 8 Administration of FeLV vaccine subcutaneously below the left
stifle. Courtesy Dr Susan Little
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